United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,258 shares of United Therapeutics Corp. stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $122.34, for a total transaction of $153,903.72. Following the completion of the sale, the chief executive officer now owns 1,398 shares of the company’s stock, valued at $171,031.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 123.44 on Wednesday. United Therapeutics Corp. has a one year low of $97.52 and a one year high of $164.04. The company has a 50-day moving average of $124.24 and a 200 day moving average of $116.01. The stock has a market cap of $5.37 billion, a price-to-earnings ratio of 5.97 and a beta of 1.46.

United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.22 by $1.33. The company had revenue of $412.60 million for the quarter, compared to analyst estimates of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The firm’s revenue was up 18.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.55 earnings per share. On average, equities analysts forecast that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.

Several analysts have commented on UTHR shares. Zacks Investment Research upgraded shares of United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $126.00 price objective for the company in a research note on Tuesday, July 26th. Jefferies Group restated a “hold” rating and set a $120.00 price objective on shares of United Therapeutics Corp. in a research note on Friday, July 29th. HC Wainwright restated a “hold” rating on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Argus restated a “hold” rating on shares of United Therapeutics Corp. in a research note on Tuesday, August 23rd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a research note on Friday, July 29th. Nine investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $135.64.

A number of institutional investors have recently made changes to their positions in the stock. Scopia Capital Management LP raised its position in shares of United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock worth $470,154,000 after buying an additional 1,370,698 shares during the period. Geode Capital Management LLC raised its position in shares of United Therapeutics Corp. by 21.1% in the first quarter. Geode Capital Management LLC now owns 455,719 shares of the biotechnology company’s stock worth $50,761,000 after buying an additional 79,502 shares during the period. UBS Asset Management Americas Inc. raised its position in shares of United Therapeutics Corp. by 7.3% in the first quarter. UBS Asset Management Americas Inc. now owns 226,285 shares of the biotechnology company’s stock worth $25,215,000 after buying an additional 15,402 shares during the period. Nuveen Asset Management LLC raised its position in shares of United Therapeutics Corp. by 10.2% in the first quarter. Nuveen Asset Management LLC now owns 65,047 shares of the biotechnology company’s stock worth $7,248,000 after buying an additional 6,014 shares during the period. Finally, Norges Bank acquired a new position in shares of United Therapeutics Corp. during the fourth quarter worth about $65,955,000.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.